VRTX stock verdict - Avoid
VRTX
VERTEX PHARMACEUTICALS INC / MA
AVOIDHealthcare
$526.19
Fundamentals below bar
$526.19
Heavy$301.75Buy$402.33Fair$502.91Exit$603.49
VALUE29
GROWTH30
QUALITY90
TECHNICAL—
TRUST SCORE
96High
confidence in this read — data completeness, earnings quality & coverage
Technicals: insufficient price history
PROS
- Strong return on equity of 21.8% (TTM)
- Revenue grew 10.4%/yr on average over the last 3 years
- Conservative balance sheet — debt-to-equity of 0.01
CONS
No red flags detected.
✳ Pros and cons are machine-generated from the latest fundamentals and technicals.
EARNINGS QUALITY · we check the accounting so you don't have to
✓Operating cash flow is 97% of net income — profit is backed by real cash
Analysis as of 2026-09-25 · price live, fundamentals from latest filings
Congress Trading — last 90 days
See what senators are buying and selling on VRTX. Sign in to unlock.
📊 Options Flow — Put/Call Ratio
FAQ
Why is VRTX rated Avoid?
VRTX (VERTEX PHARMACEUTICALS INC / MA) is rated Avoid because the model combines fundamentals, price action, and earnings-quality checks. The current signal is Fundamentals below bar. Strong return on equity of 21.8% (TTM) and Revenue grew 10.4%/yr on average over the last 3 years
Is VRTX overvalued right now?
VRTX is trading at $526.19 versus an estimated fair value of $502.91. That puts the stock in avoid territory on this framework. The page shows the specific downside checks behind that call.
What should I watch before acting on VRTX?
Watch the trust score of 96, the earnings-quality checks, and any red flags. The page includes the key cautions and a plain-English summary.